Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
12 Juli 2023 - 10:30PM
Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ:
CLLS), a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced that during the annual shareholders
meeting held on June 27, 2023, Cécile Chartier, Ph.D., has been
appointed as a Director of the Company’s Board of Directors, with
immediate effect.
“We are very excited to welcome Dr. Chartier as
a director of Cellectis’ Board of Directors. Cécile’s extensive
experience in the development of next generation cell and gene
therapies coupled with her deep knowledge of the U.S. biotechnology
industry will be a huge asset to the Company,” said André Choulika,
Ph.D., Chief Executive Officer at Cellectis. “We look forward to
her contribution and insights as we continue advancing the
development of our product candidates.”
“I am honored to have the opportunity to
contribute to the development of truly breakthrough gene editing
therapies. I am keen to lend my insights to the Cellectis’ Board of
Directors to serve a patient population with severe unmet medical
needs, where a successful allogeneic CAR T-cell product candidate
could be a major breakthrough,” said Cécile Chartier, Ph.D.,
Cellectis newest Board member.
Cécile Chartier currently serves as Chief
Scientific Officer at NextVivo, Inc. Prior to her tenure at
NextVivo, Dr. Chartier was Vice President of Research at Iovance
Biotherapeutics, Inc. where she led the development of next
generation tumor-infiltrating lymphocytes (TIL) therapies through
research to early-stage clinical trials.
Prior to this, she spent 12 years at
OncoMed Pharmaceuticals, where she served as Senior Director of
Target Validation and led multiple antibody therapeutics project
teams through Research and Development to IND
filing. She also worked at Shering (US Berlex) and Transgene
(France), where she focused on gene therapy.
Dr. Chartier obtained her Ph.D. in molecular
biology from the Université Louis Pasteur in Strasbourg, France and
pursued a post-doctoral training at Harvard Medical School.
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
23 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “expect,” “plan,” “could” and “will,” or the negative
of these and similar expressions. These forward-looking statements,
which are based on our management’s current expectations and
assumptions and on information currently available to management.
Forward-looking statements include statements about the potential
of our product candidates. These forward-looking statements are
made in light of information currently available to us and are
subject to numerous risks and uncertainties, including with respect
to the numerous risks associated with biopharmaceutical product
candidate development. With respect to our cash runway, our
operating plans, including product development plans, may change as
a result of various factors, including factors currently unknown to
us. Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2022 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
- Cellectis Appoints Cécile Chartier
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024